Targeted Therapies for Cancers
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 1352
Special Issue Editor
Interests: gynecological cancer; colon cancer; pancreatic cancer; signaling pathways; targeted therapy; precision medicine; combination therapy; recurrence mechanisms; immune-modulation; cancer stem cell targeting; rna-based therapy; cancer cell metabolism
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a leading cause of morbidity and mortality, accounting for an expected 2,001,140 new cancer cases and 611,720 cancer deaths in 2024 in the United States. It is necessary to conduct extensive research to develop new cancer treatments since cancer cells can develop resistance to conventional therapies, and resistant malignancies are becoming more prevalent. Furthermore, a better understanding of the molecular mechanisms of carcinogenesis is critical for cancer prevention, early detection, and improved prognosis. The identification of the oncogenic pathways that cause cancer cells to become treatment-resistant can accelerate the development of cancer-specific therapies.
Recent developments in molecular technology are generating a surge of cancer cell discoveries that will have a favorable impact on metastatic cancer detection and treatment in the near future. Although there are treatments in research that appear to be effective in clinical practice, many pharmaceuticals fail in clinical trials for a variety of reasons. It is challenging for a drug to successfully transition from pre-clinical research to clinical therapy. The complexity of the metastatic cascade is undoubtedly a factor in some of these failed treatments. However, these unsuccessful therapies/drugs can provide valuable information to researchers, allowing them to identify more effective therapies/drugs/targets. This strategy can help to find oncogenic pathways, mechanisms of resistance, and novel approaches to decrease tumor development and distant metastasis. Moreover, it can direct from pre-clinical models (cell lines, tumoroids, organoids, and murine models) to successful clinical trial portfolios. With advancements in nucleic acid sequencing, nanoscale biochemistry, subcellular imaging, computing power, and artificial intelligence, individualized precision diagnostics and treatments are projected to strengthen medicine in the near future.
The focus of this Special Issue will be on cutting-edge therapeutic targets for cancerous tumors that improve our comprehension of how to target this intricate pathway in human cancers. Preference will be given to manuscripts that promote inter- and/or transdisciplinary research by applying innovative conceptual thought to theoretical models, existing methodologies, and strategy applications. Authors with expertise in these pertinent study domains are encouraged to submit systematic reviews or methodological developments as well as original research studies to this Special Issue.
Dr. Iram Fatima
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- precision medicine
- combination therapy
- recurrence mechanisms
- immune modulation
- cancer stem cell targeting
- rna-based therapy
- epigenetic therapy
- cancer cell metabolism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
